{"id": "238", "gene": {"name": "AR"}, "evidence_items": ["Steinkamp MP, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res 2009;69(10):4434-42", "Lallous N, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol 2016;17(1):10"], "pmkb_evidence_tier": "1", "variants": [{"name": "AR H875Y", "id": "379"}, {"name": "AR T878A", "id": "378"}], "diseases": ["Adenocarcinoma"], "therapies": ["therapeutic procedure"], "description": "Mutations in the Androgen Receptor are rare in untreated prostate cancer and have been described in 15-33% of castration resistant prostate cancer and hormone refractory tumors.  Among these, the H875Y and T878A are recurrent mutations that have been previously described.  These mutations alter responses to androgen receptor antagonists.  Cases with two such mutations have been previously reported and the mutations may co-exist on the same allele.", "tissue_types": ["Prostate"], "origin": "Somatic"}